Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Testicular Neoplasms | 6 | 2023 | 805 | 2.510 |
Why?
|
Radiation Oncology | 6 | 2024 | 570 | 2.380 |
Why?
|
Neoplasms, Second Primary | 5 | 2023 | 1061 | 2.150 |
Why?
|
Prostatic Neoplasms | 23 | 2024 | 11094 | 1.900 |
Why?
|
Radiosurgery | 5 | 2024 | 1329 | 1.670 |
Why?
|
Seminoma | 2 | 2023 | 135 | 1.610 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 7 | 2023 | 1667 | 1.220 |
Why?
|
Urinary Bladder Neoplasms | 5 | 2024 | 2185 | 1.190 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 497 | 0.990 |
Why?
|
Salvage Therapy | 5 | 2024 | 1274 | 0.920 |
Why?
|
Penile Neoplasms | 1 | 2024 | 158 | 0.820 |
Why?
|
Radiotherapy Dosage | 9 | 2023 | 2911 | 0.810 |
Why?
|
Oropharyngeal Neoplasms | 2 | 2018 | 492 | 0.800 |
Why?
|
Neoplasms | 10 | 2024 | 22343 | 0.780 |
Why?
|
Photons | 3 | 2021 | 588 | 0.770 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2023 | 1787 | 0.760 |
Why?
|
Prostate-Specific Antigen | 7 | 2024 | 2463 | 0.740 |
Why?
|
Nerve Sheath Neoplasms | 2 | 2012 | 169 | 0.730 |
Why?
|
Radiation Injuries | 2 | 2019 | 1192 | 0.700 |
Why?
|
Radiation Tolerance | 2 | 2019 | 475 | 0.690 |
Why?
|
Physicians, Women | 2 | 2024 | 515 | 0.690 |
Why?
|
Faculty, Medical | 3 | 2024 | 1226 | 0.660 |
Why?
|
Brachytherapy | 2 | 2017 | 1220 | 0.660 |
Why?
|
Radiobiology | 1 | 2019 | 90 | 0.640 |
Why?
|
Congresses as Topic | 1 | 2024 | 811 | 0.630 |
Why?
|
Schools, Medical | 2 | 2022 | 882 | 0.630 |
Why?
|
Minority Groups | 3 | 2023 | 1208 | 0.610 |
Why?
|
Lung Neoplasms | 7 | 2021 | 13486 | 0.570 |
Why?
|
Ablation Techniques | 1 | 2020 | 253 | 0.560 |
Why?
|
Prostatectomy | 5 | 2024 | 1786 | 0.550 |
Why?
|
Rectal Neoplasms | 3 | 2021 | 1183 | 0.540 |
Why?
|
Vaginal Neoplasms | 1 | 2017 | 105 | 0.540 |
Why?
|
Urinary Bladder | 1 | 2023 | 1155 | 0.530 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2020 | 447 | 0.500 |
Why?
|
Pelvis | 1 | 2020 | 737 | 0.500 |
Why?
|
Male | 53 | 2024 | 363975 | 0.500 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2019 | 794 | 0.490 |
Why?
|
Humans | 85 | 2024 | 766432 | 0.480 |
Why?
|
Societies, Medical | 2 | 2024 | 3953 | 0.470 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 454 | 0.470 |
Why?
|
Social Class | 1 | 2023 | 2006 | 0.470 |
Why?
|
Esophagus | 2 | 2021 | 1038 | 0.460 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2018 | 614 | 0.440 |
Why?
|
Esophagogastric Junction | 1 | 2016 | 350 | 0.430 |
Why?
|
Antidiuretic Agents | 1 | 2013 | 21 | 0.430 |
Why?
|
Diabetes Insipidus, Nephrogenic | 1 | 2013 | 20 | 0.430 |
Why?
|
Neoplasm Staging | 8 | 2023 | 11217 | 0.430 |
Why?
|
Fanconi Syndrome | 1 | 2013 | 35 | 0.420 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2013 | 87 | 0.420 |
Why?
|
Radiology, Interventional | 1 | 2017 | 483 | 0.420 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4888 | 0.420 |
Why?
|
Medulloblastoma | 1 | 2018 | 679 | 0.420 |
Why?
|
Ifosfamide | 1 | 2013 | 233 | 0.410 |
Why?
|
Nephrectomy | 1 | 2018 | 928 | 0.410 |
Why?
|
Rhabdomyoma | 1 | 2012 | 56 | 0.400 |
Why?
|
Urology | 1 | 2017 | 384 | 0.400 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2015 | 287 | 0.400 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2016 | 543 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2024 | 9401 | 0.390 |
Why?
|
Poverty | 1 | 2023 | 2714 | 0.380 |
Why?
|
Colonic Neoplasms | 2 | 2021 | 2533 | 0.380 |
Why?
|
Orchiectomy | 2 | 2023 | 465 | 0.370 |
Why?
|
Uveal Neoplasms | 1 | 2014 | 344 | 0.370 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2018 | 4049 | 0.370 |
Why?
|
Neoplasm Invasiveness | 3 | 2024 | 3608 | 0.370 |
Why?
|
Preimplantation Diagnosis | 1 | 2012 | 143 | 0.350 |
Why?
|
Medical Oncology | 4 | 2023 | 2340 | 0.350 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5389 | 0.340 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1384 | 0.330 |
Why?
|
Herpesvirus 4, Human | 1 | 2015 | 1079 | 0.320 |
Why?
|
Blastocyst | 1 | 2012 | 432 | 0.320 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2012 | 323 | 0.320 |
Why?
|
Radiation Dosage | 1 | 2017 | 1952 | 0.320 |
Why?
|
Neoadjuvant Therapy | 2 | 2021 | 2902 | 0.310 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2015 | 616 | 0.310 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 6508 | 0.310 |
Why?
|
United States | 13 | 2024 | 72910 | 0.300 |
Why?
|
Cultural Diversity | 2 | 2022 | 370 | 0.290 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 1380 | 0.290 |
Why?
|
Prostate | 7 | 2024 | 1757 | 0.290 |
Why?
|
Neurofibromatosis 1 | 1 | 2012 | 561 | 0.280 |
Why?
|
Carcinoma, Papillary | 1 | 2012 | 791 | 0.280 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26294 | 0.280 |
Why?
|
Glioma | 2 | 2019 | 3498 | 0.270 |
Why?
|
Fetal Hemoglobin | 3 | 2015 | 346 | 0.270 |
Why?
|
Female | 29 | 2024 | 396354 | 0.260 |
Why?
|
Quality of Life | 4 | 2024 | 13472 | 0.260 |
Why?
|
Carcinoma, Renal Cell | 1 | 2021 | 3186 | 0.260 |
Why?
|
Treatment Outcome | 12 | 2023 | 65202 | 0.260 |
Why?
|
Thyroid Gland | 1 | 2012 | 1170 | 0.260 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 5535 | 0.260 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8042 | 0.250 |
Why?
|
Esophageal Neoplasms | 1 | 2016 | 1660 | 0.250 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1474 | 0.250 |
Why?
|
Thyroid Nodule | 1 | 2012 | 765 | 0.250 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5334 | 0.240 |
Why?
|
Kidney Neoplasms | 1 | 2021 | 4282 | 0.240 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2017 | 2039 | 0.230 |
Why?
|
Fertilization in Vitro | 1 | 2012 | 1301 | 0.230 |
Why?
|
Physicians | 1 | 2022 | 4591 | 0.230 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20706 | 0.230 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5509 | 0.220 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 105 | 0.220 |
Why?
|
Middle Aged | 18 | 2024 | 223127 | 0.210 |
Why?
|
Aged | 16 | 2024 | 171234 | 0.210 |
Why?
|
Pediatrics | 1 | 2018 | 3613 | 0.210 |
Why?
|
Mortality | 2 | 2024 | 2907 | 0.210 |
Why?
|
Magnetic Resonance Imaging | 7 | 2023 | 36562 | 0.210 |
Why?
|
Ataxia Telangiectasia | 1 | 2023 | 107 | 0.210 |
Why?
|
Aged, 80 and over | 8 | 2024 | 59538 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3109 | 0.210 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2839 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3231 | 0.200 |
Why?
|
Combined Modality Therapy | 3 | 2023 | 8536 | 0.200 |
Why?
|
Adult | 17 | 2024 | 223253 | 0.190 |
Why?
|
Mutation | 4 | 2024 | 30220 | 0.180 |
Why?
|
Young Adult | 8 | 2024 | 59928 | 0.180 |
Why?
|
Brain Neoplasms | 2 | 2019 | 9101 | 0.180 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3236 | 0.170 |
Why?
|
Retrospective Studies | 12 | 2024 | 81588 | 0.170 |
Why?
|
Policy | 1 | 2023 | 512 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 11872 | 0.160 |
Why?
|
Cystectomy | 1 | 2023 | 603 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2355 | 0.160 |
Why?
|
Socioeconomic Factors | 2 | 2023 | 7840 | 0.160 |
Why?
|
Disease-Free Survival | 3 | 2024 | 6845 | 0.150 |
Why?
|
Canada | 1 | 2024 | 2123 | 0.150 |
Why?
|
Personnel Selection | 1 | 2020 | 201 | 0.150 |
Why?
|
Evidence-Based Practice | 1 | 2022 | 499 | 0.150 |
Why?
|
Organs at Risk | 1 | 2020 | 365 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 3552 | 0.150 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6545 | 0.150 |
Why?
|
Tumor Burden | 2 | 2023 | 1900 | 0.150 |
Why?
|
Demography | 1 | 2022 | 1641 | 0.150 |
Why?
|
Cisplatin | 1 | 2023 | 1656 | 0.140 |
Why?
|
Prognosis | 5 | 2024 | 29922 | 0.140 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 12527 | 0.140 |
Why?
|
Rectum | 1 | 2021 | 896 | 0.130 |
Why?
|
Bleomycin | 1 | 2017 | 491 | 0.130 |
Why?
|
Incidence | 3 | 2024 | 21509 | 0.130 |
Why?
|
Protons | 1 | 2021 | 1097 | 0.130 |
Why?
|
Vinblastine | 1 | 2017 | 482 | 0.130 |
Why?
|
Hemoglobinopathies | 2 | 2013 | 101 | 0.130 |
Why?
|
Educational Status | 1 | 2023 | 2510 | 0.130 |
Why?
|
Survival Rate | 3 | 2019 | 12825 | 0.130 |
Why?
|
Erythroid Cells | 2 | 2015 | 237 | 0.120 |
Why?
|
Fatigue | 1 | 2022 | 1554 | 0.120 |
Why?
|
Genomics | 4 | 2024 | 5924 | 0.120 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2017 | 877 | 0.120 |
Why?
|
Prospective Studies | 5 | 2023 | 54826 | 0.120 |
Why?
|
Risk | 2 | 2020 | 9601 | 0.120 |
Why?
|
Income | 1 | 2023 | 1875 | 0.120 |
Why?
|
Dacarbazine | 1 | 2017 | 552 | 0.120 |
Why?
|
Cost Savings | 1 | 2019 | 902 | 0.110 |
Why?
|
Polyuria | 1 | 2013 | 37 | 0.110 |
Why?
|
Data Collection | 1 | 2022 | 3321 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2022 | 1411 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2017 | 492 | 0.110 |
Why?
|
Consensus | 4 | 2024 | 3198 | 0.100 |
Why?
|
Single Embryo Transfer | 1 | 2012 | 29 | 0.100 |
Why?
|
Leadership | 1 | 2022 | 1394 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2024 | 1876 | 0.100 |
Why?
|
Weight Gain | 1 | 2022 | 2356 | 0.100 |
Why?
|
Intussusception | 1 | 2013 | 114 | 0.100 |
Why?
|
Adolescent | 6 | 2019 | 88898 | 0.100 |
Why?
|
Papillomaviridae | 1 | 2017 | 1138 | 0.090 |
Why?
|
Administration, Intranasal | 1 | 2013 | 482 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1765 | 0.090 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1998 | 0.090 |
Why?
|
Doxorubicin | 1 | 2017 | 2228 | 0.090 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3943 | 0.090 |
Why?
|
Retinal Detachment | 1 | 2014 | 429 | 0.090 |
Why?
|
Propensity Score | 1 | 2017 | 1972 | 0.080 |
Why?
|
Pregnancy Rate | 1 | 2012 | 654 | 0.080 |
Why?
|
Radiotherapy | 1 | 2016 | 1497 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2014 | 2920 | 0.080 |
Why?
|
Gene Silencing | 1 | 2015 | 1505 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2947 | 0.080 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2017 | 2028 | 0.080 |
Why?
|
Biomedical Research | 1 | 2024 | 3458 | 0.080 |
Why?
|
Embryo Transfer | 1 | 2012 | 526 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4248 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39283 | 0.070 |
Why?
|
Medical Records | 1 | 2012 | 1408 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3690 | 0.070 |
Why?
|
Thyroidectomy | 1 | 2012 | 912 | 0.070 |
Why?
|
Enhancer Elements, Genetic | 1 | 2013 | 1363 | 0.070 |
Why?
|
RNA Interference | 1 | 2015 | 2825 | 0.070 |
Why?
|
Transcriptional Activation | 1 | 2012 | 1749 | 0.070 |
Why?
|
Mass Screening | 1 | 2022 | 5451 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15390 | 0.060 |
Why?
|
Cell Lineage | 1 | 2015 | 2573 | 0.060 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 3424 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5367 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11059 | 0.060 |
Why?
|
Papillomavirus Infections | 1 | 2017 | 1638 | 0.060 |
Why?
|
Registries | 1 | 2021 | 8344 | 0.060 |
Why?
|
Child | 4 | 2019 | 80668 | 0.060 |
Why?
|
Databases, Factual | 2 | 2018 | 8061 | 0.060 |
Why?
|
Time Factors | 3 | 2017 | 40116 | 0.060 |
Why?
|
Visual Acuity | 1 | 2014 | 2714 | 0.060 |
Why?
|
Parents | 1 | 2018 | 3595 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 4047 | 0.060 |
Why?
|
Carrier Proteins | 2 | 2015 | 4924 | 0.060 |
Why?
|
Cause of Death | 1 | 2014 | 3714 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8729 | 0.060 |
Why?
|
Retina | 1 | 2014 | 2656 | 0.050 |
Why?
|
Carcinoma | 1 | 2015 | 2323 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2018 | 2928 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9521 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13639 | 0.050 |
Why?
|
Informatics | 1 | 2023 | 72 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9458 | 0.050 |
Why?
|
Cohort Studies | 2 | 2023 | 41703 | 0.050 |
Why?
|
Nuclear Proteins | 2 | 2015 | 5794 | 0.050 |
Why?
|
Gallium Radioisotopes | 1 | 2022 | 195 | 0.050 |
Why?
|
Survival Analysis | 1 | 2014 | 10092 | 0.050 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 428 | 0.050 |
Why?
|
Disease Progression | 2 | 2018 | 13632 | 0.050 |
Why?
|
Sarcoma | 1 | 2012 | 1802 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 124 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2825 | 0.050 |
Why?
|
Internship and Residency | 1 | 2020 | 5944 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 24272 | 0.040 |
Why?
|
Ultrasonography | 1 | 2012 | 5988 | 0.040 |
Why?
|
MicroRNAs | 1 | 2015 | 3788 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12061 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7426 | 0.040 |
Why?
|
Cell Growth Processes | 1 | 2019 | 380 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1105 | 0.040 |
Why?
|
Child, Preschool | 2 | 2018 | 42576 | 0.040 |
Why?
|
Hydrogels | 1 | 2023 | 729 | 0.040 |
Why?
|
Delphi Technique | 1 | 2021 | 892 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12979 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2022 | 1707 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 8925 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 11919 | 0.030 |
Why?
|
Gene Order | 1 | 2015 | 164 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2012 | 11648 | 0.030 |
Why?
|
Androgens | 1 | 2022 | 1279 | 0.030 |
Why?
|
gamma-Globins | 1 | 2015 | 105 | 0.030 |
Why?
|
DNA Repair | 1 | 2023 | 2048 | 0.030 |
Why?
|
DNA Damage | 1 | 2023 | 2464 | 0.030 |
Why?
|
Repressor Proteins | 2 | 2015 | 2977 | 0.030 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2013 | 96 | 0.030 |
Why?
|
Retroviridae | 1 | 2015 | 845 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2015 | 898 | 0.020 |
Why?
|
Biopsy | 1 | 2024 | 6778 | 0.020 |
Why?
|
Nucleic Acid Conformation | 1 | 2015 | 899 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 6967 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2013 | 856 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1602 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2013 | 15818 | 0.020 |
Why?
|
Pregnancy | 1 | 2012 | 30235 | 0.020 |
Why?
|
Gene Targeting | 1 | 2013 | 840 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2024 | 3928 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4055 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2660 | 0.020 |
Why?
|
Genetic Engineering | 1 | 2013 | 935 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 21157 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2015 | 3400 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3403 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2013 | 4618 | 0.020 |
Why?
|
Base Sequence | 1 | 2015 | 12412 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2015 | 5789 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7583 | 0.010 |
Why?
|
Chromatin | 1 | 2013 | 2979 | 0.010 |
Why?
|
Cell Line | 1 | 2015 | 15563 | 0.010 |
Why?
|
Massachusetts | 1 | 2013 | 8885 | 0.010 |
Why?
|
Genetic Variation | 1 | 2013 | 6612 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2013 | 18979 | 0.010 |
Why?
|
Mice | 2 | 2015 | 81863 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 17082 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12807 | 0.010 |
Why?
|
Transcription Factors | 1 | 2013 | 12147 | 0.010 |
Why?
|
Animals | 2 | 2015 | 168887 | 0.010 |
Why?
|
Infant | 1 | 2013 | 36460 | 0.010 |
Why?
|
Risk Factors | 1 | 2013 | 74828 | 0.000 |
Why?
|